Piper Jaffray Reiterates Overweight Rating On OMCL

Piper Jaffray has reported a maintained Overweight Rating on Omnicell Inc. OMCL. According to Piper Jaffray, "Proposed Stage 2 Meaningful Use requirements require automated tracking of 30% of medication orders, which we believe will be a catalyst for the sale of automated medication dispensing cabinets. Quantifying this opportunity based on a top-down model, we see 25% upside to FY12 consensus. We anticipate further clarity when the HHS issues final stage 2 requirements this summer. We are buyers here; reiterate Overweight rating, $17 target." OMCL closed at $13.94 yesterday.